Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1048
  • Home
  • Print this page
  • Email this page
CASE REPORT

Occurrence of Type 1 Diabetes in a Patient Enrolled in an Immunotherapy Combination Phase 1 Clinical Trial: A Case Study


 Department of Investigational Cancer Therapeutics (A Phase 1 Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA

Correspondence Address:
Sheena Charles,
Department of Investigational Cancer Therapeutics (A Phase 1 Program), University of Texas MD Anderson Cancer Center, Houston, TX
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/apjon.apjon-2122

Advances in cancer immunotherapy treatments have shown promising results in patients with metastatic malignancy who have been refractory to prior treatments. Immune checkpoint inhibitors such as pembrolizumab in combination with other systemic agents may unleash immune-related adverse events (irAEs). Immunotherapy-induced Type 1 diabetes is rare; however, if left undiagnosed, it may cause life-threatening metabolic endocrinopathies. Advanced practice registered nurses are in a unique position to recognize and identify this irAE and in doing so can provide pathways for early diagnosis and treatments, thus leading to improved clinical and patient outcomes.


 Table of Contents

  Search Pubmed for
 
    -  Charles S
    -  Poullard A
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed255    
    PDF Downloaded9    

Recommend this journal